In early 2020, I was in a virtual green room at one of our industry’s major conferences. As we were preparing for a panel discussion, the host asked me: so that 2020 Trends report, looks like you missed a pretty big one, right?
OXFORD, UK – 19 October 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ImplaVax® enabled pandemic flu vaccine.
Oxford, UK, 19 October 2021 – Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, has expanded its R&D capabilities by taking new laboratory and office space in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies.
Provides roadmap to commercial agreement based on shared objective to secure patient access to innovative and cost-effective cancer medicines
Agreement with one of the largest public healthcare systems globally demonstrates EQRx’s commitment to offering new medicines to patients at radically lower prices
EQRx’s lead cancer programs, aumolertinib and sugemalimab, have received Innovation Passport designations through the Innovative Licensing and Access Pathway (ILAP)
Leading biotech product development consultancy Boyds has added two experienced product development experts to its team, amid growing demand for specialist Product Development services from clients in the UK, Europe and the US.
Next week the Chancellor will deliver the Comprehensive Spending Review and Budget. We are working hard to get our sector’s needs across to Ministers and Treasury officials. In a final push this week we are coordinating letters from BIA members to the Chancellor calling on him to increase Innovate UK’s budget, plus protecting and expanding R&D tax credits. Please help by sending your own short email to the Chancellor, explaining how these things have helped your business, both to email@example.com and Martin Turner our Head of Policy and Public Affairs who is organising our efforts.
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announced plans today to offer contract development and manufacturing services. CTI will launch the new initiative, focusing on offerings that will enhance cell and gene therapy capabilities.
A record £3 billion has been raised by our sector in the first three quarters of 2021 according to our latest data released today with Clarivate. With £576m raised between June and the end of August, fundraising in 2021 has already surpassed the previous record year of 2020, when £2.8 billion was raised, with another three months of the year left to go.
A record £3 billion has been raised by the UK biotech and life science sector in the first three quarters of 2021, according to new data released today by the BioIndustry Association (BIA) and Clarivate. With £576m raised between June and the end of August, fundraising in 2021 has already surpassed the previous record year of 2020, when £2.8 billion was raised, with another three months of the year left to go.